Home Biosimilar Antibodies Immunology & Inflammation Immunology & Inflammation related Magrolimab (anti-CD47)
For research use only. Not for use in humans.

Magrolimab (anti-CD47)

Synonyms: IAP， CD47

Magrolimab (anti-CD47) (5F9, GS-4721,Hu5F9 G4,ONO 7913) is a first-in-class macrophage immune checkpoint inhibitor that mainly binds to N-terminal pyroglutamate of CD47.

Magrolimab (anti-CD47)

Click to purchase the isotype control of Magrolimab (anti-CD47)

2 Citations

The Nobel Prize

17 Nobel Prize winners have used Selleck products

Shimon Sakaguchi

Nature Communications 2025,16, Article number:1325

David Baker

Dev Cell 2023, 58(20):2163-2180.e9.

David Julius

Cell 2017, 185-198.e16

Michael Houghton

Cell Chem Biol, 2020, 27(7):780-792.e5

Charles M. Rice

Cell 2018, 172(3):423-438.e25

Quality Control

Batch: A203604 Purity: 99% Protein concentration: 7.31mg/ml Endotoxin Level: ＜1EU/mg
99

Specificity

Expand to Check More
1. "+" indicates inhibitory effect. Increased inhibition is marked by a higher "+" designation. 2. "✔" indicates inhibitory effect, but without specific value.

Mechanism of Action

Description

Magrolimab (anti-CD47) (5F9, GS-4721,Hu5F9 G4,ONO 7913) is a first-in-class macrophage immune checkpoint inhibitor that mainly binds to N-terminal pyroglutamate of CD47.
References

Product Details

CAS No. 2169232-81-7
Molecular Weight 146 KD
Isotype Human IgG4
Application Magrolimab (anti-CD47)
Source CHO cells
Sterility 0.2 μM filtered
Formulation PBS Buffer, PH 7.4
Storage
(From the date of receipt)		 Store the undiluted solution at 4°C in the dark to avoid freeze-thaw cycles.

Comparison of Clones for

*Literature analysis of various clone (for this target) products available on the market shows that Selleck's selected clones are more frequently applied. (data until September 2024)

Clinical Trial Information

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT05367401 WITHDRAWN Drug: Sabatolimab|Drug: Magrolimab|Drug: Azacitidine Myelodysplastic Syndromes; Acute Myeloid Leukemia Novartis Pharmaceuticals 2024-12-20 PHASE1; PHASE2
NCT05829434 WITHDRAWN Drug: Magrolimab|Drug: 7+3|Drug: CPX-351 Acute Myeloid Leukemia; Myelodysplastic Neoplasm Uwe Platzbecker 2024-03-31 PHASE2
NCT06642792 RECRUITING Drug: AK129|Drug: AK117 Classic Hodgkin Lymphoma Akeso 2025-01-17 PHASE1; PHASE2
NCT05229497 ACTIVE_NOT_RECRUITING Drug: AK112|Drug: AK117|Drug: Carboplatin|Drug: Cisplatin|Dr Advanced Malignant Tumors Akeso 2022-05-04 PHASE1; PHASE2
NCT05807126 WITHDRAWN Drug: Olaparib Anatomic Stage IV Breast Cancer AJCC v8; Castration-Resistant Prostate Carcinoma; Stage IVB Prostate Cancer AJCC v8 National Cancer Institute (NCI) 2024-03-05 PHASE1
NCT06508606 ACTIVE_NOT_RECRUITING Drug: AK117 + Cetuximab|Drug: AK117 + AK104 Head and Neck Squamous Cell Carcinoma West China Hospital 2024-08-01 PHASE2

(data from https://clinicaltrials.gov, updated on 2024-04-11)

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.